BioLargo Reports Q2 2025 Operating and Financial Results
BioLargo (OTCQX:BLGO), a cleantech and environmental solutions company, reported its Q2 2025 financial results with revenues of $2.77 million for Q2 and $6.04 million for H1 2025. The company highlighted significant progress across multiple divisions, with its engineering segment experiencing a 517% revenue increase in air quality control services.
Notable achievements include Clyra Medical Technologies securing distribution agreements covering 6,100 hospitals and thousands of medical facilities, while the company's Cellinity battery technology received validation from U.S. BESS Corporation and secured four MOUs for potential factory partnerships. As of June 30, 2025, BioLargo maintained a strong financial position with $3.47 million in cash, total assets of $12.49 million, and stockholders' equity of $6.06 million.
BioLargo (OTCQX:BLGO), azienda cleantech e di soluzioni ambientali, ha comunicato i risultati finanziari del secondo trimestre 2025, registrando ricavi per $2.77 million nel Q2 e $6.04 million nel primo semestre 2025. La societ脿 ha evidenziato progressi significativi in pi霉 divisioni, con il suo segmento ingegneristico che ha mostrato un aumento dei ricavi del 517% nei servizi di controllo della qualit脿 dell'aria.
Tra i risultati di rilievo, Clyra Medical Technologies ha assicurato accordi di distribuzione che coprono 6.100 ospedali e migliaia di strutture sanitarie, mentre la tecnologia per batterie Cellinity ha ottenuto la validazione da parte di U.S. BESS Corporation e ha siglato quattro memorandum d'intesa per potenziali partnership di produzione. Al 30 giugno 2025 BioLargo manteneva una solida posizione finanziaria con $3.47 million in cash, attivit脿 totali per $12.49 million e patrimonio netto di $6.06 million.
BioLargo (OTCQX:BLGO), empresa cleantech y de soluciones medioambientales, present贸 sus resultados financieros del segundo trimestre de 2025 con ingresos de $2.77 million en el Q2 y $6.04 million en el primer semestre de 2025. La compa帽铆a destac贸 progresos significativos en varias divisiones, con su segmento de ingenier铆a experimentando un aumento de ingresos del 517% en servicios de control de la calidad del aire.
Entre los logros notables, Clyra Medical Technologies asegur贸 acuerdos de distribuci贸n que cubren 6,100 hospitales y miles de centros m茅dicos, mientras que la tecnolog铆a de bater铆as Cellinity recibi贸 validaci贸n por parte de U.S. BESS Corporation y formaliz贸 cuatro memorandos de entendimiento para posibles asociaciones fabriles. Al 30 de junio de 2025, BioLargo manten铆a una s贸lida posici贸n financiera con $3.47 million en efectivo, activos totales por $12.49 million y patrimonio de los accionistas de $6.06 million.
BioLargo (OTCQX:BLGO)電� 韥措Π韰岉伂 氚� 頇橁步 靻旊（靺� 旮办梾鞙茧, 2025雲� 2攵勱赴 鞁れ爜鞚� 氚滍憸頃橂┌ 2攵勱赴 毵れ稖 $2.77 million, 2025雲� 靸侂皹旮� 毵れ稖 $6.04 million鞚� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 鞐煬 靷梾攵�鞐愳劀 欷戩殧頃� 歆勳爠鞚� 氤挫榾鞙茧┌, 鞐旍雼堨柎毵� 攵�氍胳潃 雽�旮办 甏�毽� 靹滊箘鞀れ棎靹� 毵れ稖鞚� 517% 歃濌皜頄堨姷雼堧嫟.
欤检殧 靹标臣搿滊姅 Clyra Medical Technologies臧� 6,100臧� 氤戩洂 氚� 靾橃矞 臧� 鞚橂鞁滌劋鞚� 韽暔頃橂姅 鞙犿喌 瓿勳暯鞚� 頇曤炒頃� 鞝愱臣, Cellinity 氚绊劙毽� 旮办垹鞚� U.S. BESS Corporation鞚� 瓴�歃濎潉 氚涭晿瓿� 鞛犾灛鞝� 瓿奠灔 韺岉姼雱堨嫮鞚� 鞙勴暅 4瓯挫潣 鞏戫暣臧侅劀毳� 觳搓舶頃� 鞝愳澊 鞛堨姷雼堧嫟. 2025雲� 6鞗� 30鞚� 旮办 BioLargo電� $3.47 million鞚� 順勱笀, 齑濎瀽靷� $12.49 million, 攴鸽Μ瓿� 欤检＜歆�攵�(鞛愲掣齑濌硠) $6.06 million鞚� 氤挫湢頃橂┌ 鞎堨爼鞝侅澑 鞛 靸來儨毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟.
BioLargo (OTCQX:BLGO), entreprise cleantech et de solutions environnementales, a communiqu茅 ses r茅sultats financiers du deuxi猫me trimestre 2025, avec des revenus de $2.77 million pour le T2 et $6.04 million pour le premier semestre 2025. La soci茅t茅 a mis en avant des progr猫s significatifs dans plusieurs divisions, son segment ing茅nierie ayant connu une hausse des revenus de 517% dans les services de contr么le de la qualit茅 de l'air.
Parmi les r茅alisations notables, Clyra Medical Technologies a obtenu des accords de distribution couvrant 6 100 h么pitaux et des milliers d'茅tablissements m茅dicaux, tandis que la technologie de batteries Cellinity a 茅t茅 valid茅e par la U.S. BESS Corporation et a s茅curis茅 quatre protocoles d'entente pour d'茅ventuels partenariats de fabrication. Au 30 juin 2025, BioLargo affichait une situation financi猫re solide avec $3.47 million de liquidit茅s, des actifs totaux de $12.49 million et des capitaux propres de $6.06 million.
BioLargo (OTCQX:BLGO), ein Cleantech- und Umweltl枚sungsunternehmen, meldete seine Finanzergebnisse f眉r das zweite Quartal 2025 mit Ums盲tzen von $2.77 million im Q2 und $6.04 million im ersten Halbjahr 2025. Das Unternehmen hob erhebliche Fortschritte in mehreren Gesch盲ftsbereichen hervor, wobei das Ingenieursegment einen Umsatzanstieg von 517% bei Dienstleistungen zur Luftqualit盲tskontrolle verzeichnete.
Zu den bemerkenswerten Erfolgen z盲hlt, dass Clyra Medical Technologies Vertriebsvereinbarungen f眉r 6.100 Krankenh盲user und tausende medizinische Einrichtungen abschloss, w盲hrend die Cellinity-Batterietechnologie von der U.S. BESS Corporation validiert wurde und vier Absichtserkl盲rungen f眉r m枚gliche Fabrikpartnerschaften sicherte. Zum 30. Juni 2025 verf眉gte BioLargo 眉ber $3.47 million an Barmitteln, Gesamtverm枚gen von $12.49 million und ein Eigenkapital von $6.06 million.
- Engineering segment revenue increased by 517% from air quality control services
- Secured distribution agreements covering 6,100 hospitals, 6,300 surgery centers, and 2,200 wound care clinics
- Cellinity battery technology received validation from U.S. BESS Corporation
- Signed four MOUs for potential Cellinity battery factory partnerships
- Strong cash position of $3.47 million with $12.49 million in total assets
- Decreased revenue from Pooph pet odor product sales
- Market cap of $50 million potentially undervalues company assets according to management
Significantly Advances Energy Technologies and Clyra Medical Technologies
WESTMINSTER, CA / / August 13, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that its Quarterly Report for the three and six months ended June 30, 2025. To view the filing in its entirety, please see:
.
BioLargo, Inc. President and CEO Dennis P. Calvert, commented, "Over the past few months and quarters, our team has done a tremendous job in progressing the value of the BioLargo portfolio. The unseen value is many multiples of our current
Key Highlights:
Q2 2025 and 1st Half 2025 revenues of
$2,777,000 and$6,046,000 , respectively, primarily due to a decreased volume of sales of Pooph, our pet odor product private labeled to a third party.New engineering contracts to provide air quality control compliance services increased engineering segment revenue by
517% .Clyra Medical Technologies secured a series of sales and distribution agreements covering both U.S. and international markets, expected to make Clyra's products available by 6,100 hospitals, 6,300 ambulatory surgery centers and 2,200 specialty wound care clinics in the U.S. alone.
Independent evaluation conducted by U.S. BESS Corporation, an expert provider of advanced energy storage solutions for critical infrastructure applications, confirmed breakthrough performance of BioLargo's Cellinity battery technology for grid-scale energy storage.
Cellinity, our revolutionary battery technology, signed four memoranda of understanding (MOUs) with perspective joint venture partners interested in building and operating Cellinity battery factories.
Garratt Callahan, our co-development technology partners, continued support selling and business development targeting reuse of cooling tower water, for example at data centers.
Engineering & Environmental Services is actively engaged with clients developing scope of work and budgeting for several significant projects.
At June 30, 2025, stockholders' equity was
$6.06 0,000, assets were$12,499,000 , liabilities were$6,439,000 , and the Company had$3,471,000 in cash and cash equivalents.
Learn more about BioLargo's environmental technologies at
About BioLargo, Inc.
BioLargo, Inc. (OTCQX: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc.
View the original on ACCESS Newswire
FAQ
What were BioLargo's (BLGO) Q2 2025 revenue results?
How much did BioLargo's engineering segment revenue grow in Q2 2025?
What is the market reach of Clyra Medical Technologies' distribution agreements?
What is BioLargo's financial position as of June 30, 2025?
What progress has BioLargo made with its Cellinity battery technology?
